GlobeNewswire by notified

Nextensa : The new office building WHITE HOUSE located in the Cloche d'Or district fully let to an international company



Brussels, 13 March 2023, 5.40 pm

The new office building WHITE HOUSE located in the Cloche d'Or district fully letto an international company

Developers Nextensa and Promobe announce that they have signed a 9 year lease with a triple AAA tenant for the occupation of their WHITE HOUSE building located in the new Cloche d'Or district. The future tenant will occupy the entire WHITE HOUSE building and the ground floor and first floor in the building next door, EMERALD, for a total surface area of 8,300 sqm.

The White House building
WHITE HOUSE, designed by the architectural firm VALENTINY, will be delivered in the last quarter of 2023. The building will be leased as of the first quarter of 2024.
The office building will be developed over 7 above-ground levels and a basement level that will accommodate 40 parking spaces.

The WHITE HOUSE, with a total surface area of 6,500 sqm, is certified BREEAM excellent**. Last but not least, it is the first building to use the CRREM® - Carbon Risk Real Estate Monitor ***- method which accelerates the decarbonisation and climate change resilience of the real estate sector in the EU. The method aims to integrate carbon efficiency into investment decisions by clearly assessing the financial risks associated with poor energy performance and quantifying the financial costs. 

The EMERALD building
EMERALD, designed by architect Andrew Philips, will be delivered in the third quarter of 2023. 70% of the building will be leased as of the first quarter of 2024, with the 2 remaining floors to be let.

The office building will also be developed over 7 above-ground levels and a basement level that will accommodate 40 parking spaces. EMERALD, with a total surface area of 6,800 sqm, has been awarded a BREEAM excellent** certification.

WHITE HOUSE and EMERALD will benefit from easy access by car (motorway exit and P+R parking less than 5 minutes away) and excellent access to public transport. The upcoming arrival of the tramway with a stop within short walking distance will further increase the attractiveness of the area (end of 2023).

As the world leader in cross-border fund distribution, the second largest investment fund centre in the world and the largest in Europe, Luxembourg has benefited from the arrival of many major financial institutions, which contributes to the country's economic attractiveness.

Cloche d’Or neighborhood
The building is ideally located in the popular Cloche d'Or district, a district inspired by the concept of the ¼ hour city, which brings together in one place all the elements for a modern and harmonious life.

This new district development, one of the fastest in the country, brings together remarkable mixed architectural buildings and modern infrastructures: local shops (grocery shops, restaurants, etc.), a shopping centre, a medical centre, as well as a Kieser training centre and the future large park in Luxembourg (more than 12 ha), which will be delivered in autumn 2023.

Currently, some 25,000 people live, study, work or play in this new district. And by 2035, there will be more than 45,000 people. The Cloche d'Or district has been awarded DGNB Platinum* certification. The Cloche d'Or development is a joint venture between developers Promobe and Nextensa.

The developers
Promobe is a major player in real estate development in the Grand Duchy of Luxembourg. 

Nextensa is a mixed real estate investor and developer with activities focused on offices, retail and residential projects in the Grand Duchy of Luxembourg, Belgium and Austria. 

For more information

Michel Van Geyte,
Chief Executive Officer
+32 3 238 98 77

Media relations : Laurence Brix
Group Marketing & Communication Manager
+352 621 892 100

GROSSFELD (joint venture between Promobe and Nextensa)
Investor Relations : Patrick Labey
+352 248393-1

*The DGNB system is based on the three core areas of sustainability, namely ecology, economy and socio-cultural issues, which are equally weighted in the assessment. The DGNB system assesses location as well as technical and procedural quality in a holistic approach. The performance of these qualities can be assessed by means of certification criteria. These are tailored to different types of use and can be applied to new buildings, existing buildings, renovations and buildings in use.

**BREEAM (BRE Environmental Assessment Method) is a UK environmental certification scheme issued by the BRE (Building Research Establishment).

*** The CRREM defines decarbonisation objectives (pathways) in order to limit the global warming committed by the EU to the agreements reached in Paris.


To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

TRESU Investment Holding A/S – Registration for investor call28.3.2023 11:04:29 CEST | Press release

TRESU INVESTMENT HOLDING A/S ANNOUNCEMENT NO. 02.2023 28.03.2022 TRESU Investment Holding A/S is pleased to invite you to the financial results call, which is being held: Wednesday, 5 April 2022, at 11am CET. The Annual Report will be presented by Christian Jacob Flarup, CEO and Torben Børsting, CFO. After the presentation there will be an opportunity for Q+A. A recording of the results call will be made available for four hours on the TRESU IR website. To register for the investor call, please send an e-mail to Financial manager at TRESU A/S Finn Holm no later than 4 April 2023 9am CET - Christian Jacob Flarup CEO, TRESU For further details, please contact: CEO, Christian Jacob Flarup, phone: +45 2027 7971 CFO, Torben Børsting, phone: +45 5130 2780 Attachment Quarterly reporting - Call - 2022 Q4

Alvotech Provides Update on Corporate Sustainability Framework28.3.2023 11:00:00 CEST | Press release

Alvotech (Nasdaq: ALVO) (the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced an update to the Company’s Corporate Sustainability framework, including the release of key environmental, social and governance (“ESG”) indicators for 2022. “As part of our commitment to improve the sustainability of healthcare by providing access to more affordable biologic medicines, we recognize that corporate sustainability is closely linked to our long-term success and the value we may bring to patients, healthcare providers and all of our stakeholders,” said Robert Wessman, Founder, Chairman and CEO of Alvotech. Data on key ESG indicators for 2020-2022 can be found on Alvotech’s dedicated web portal. Alvotech’s Board of Directors has established a Corporate Sustainability Committee (CSC) to oversee the Company’s strategy as it relates to ESG matters. Alvotech’s corporate headquarters, purpose-built manuf

Zealand Pharma Announces Positive Phase 1 Clinical Results with Amylin Analogue ZP839628.3.2023 10:54:21 CEST | Press release

Company announcement – No. 7 / 2023 Zealand Pharma Announces Positive Phase 1 Clinical Results with Amylin Analogue ZP8396 Dose-dependent body weight reductions of up to a mean of 4.2% from baseline (4.8% placebo corrected) following a single dose of ZP8396In development as a non-incretin peptide therapyfor the potential management of overweight and obesity Copenhagen, Denmark, March 28, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) (CVR-no. 20045078) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced Phase 1a results for ZP8396, the company’s amylin analogue. The first-in-human study was designed to assess safety, pharmacokinetic (PK) and pharmacodynamic effects of ZP8396 in healthy lean and overweight people. “We are excited by the potential of amylin as an alternative, non-incretin treatment for overweight and obesity, and are very encouraged that treatment with a single dose of ZP8396 led to meaningful dose

Indkaldelse til ordinær generalforsamling i SKAKO A/S28.3.2023 10:50:52 CEST | pressemeddelelse

Til NASDAQ OMX Copenhagen A/S GlobeNewswire Faaborg, den 28. marts 2023 Selskabsmeddelelse nr. 5/2023 Indkaldelse til ordinær generalforsamling i SKAKO A/S SKAKO A/S indkalder til ordinær generalforsamling i selskabet til afholdelse onsdag den 19. april 2023, kl. 15.00 på selskabets adresse. Indkaldelsen er sket jf. selskabets vedtægter § 7 og er tilgængelig på selskabets hjemmeside. Udbytte På baggrund af det stærke resultat i 2022 og kapitalstrukturen i SKAKO A/S pr. 31. december 2022 anbefaler bestyrelsen en udbytteudlodning på DKK 5 pr. aktie svarende til 61,0% af årets resultat og en samlet udbytteudlodning på DKK 15,4 mio. Med en aktiekurs på 62,6 kr. pr. 31. december 2022 svarer det til en udbytteprocent på 8,0%. Udbyttebetalingen vil være et behandlingspunkt på agendaen for den ordinære generalforsamling 19. april 2023. Ex-udbytte dato: 19. april 2023 Optagelsesdato: 20. april 2023 Udbetalingsdato: 24. april 2023 Med venlig hilsen SKAKO A/S Jens Wittrup Willumsen Bestyrelsesfor

Aalborg Boldspilklub A/S indkalder til ordinær generalforsamling28.3.2023 10:50:49 CEST | pressemeddelelse

NASDAQ Copenhagen A/S Børsmeddelelse nr. 2023/06 Aalborg, 28. marts 2023 Vedhæftet indkaldelse og dagsorden til ordinær generalforsamling i Aalborg Boldspilklub A/S onsdag 19. april 2023 kl. 16.00 på Aalborg Portland Park. Venlig hilsen Aalborg Boldspilklub A/S Thomas Bælum Administrerende direktør For yderligere oplysninger: Thomas Bælum 2251 7901 Vedhæftede filer Dagsorden 2023 - Inkl Bilag A og Bilag BAAB_ Brevstemme blanket_GF2023_v5